Evolution of glycopeptide MICs in MRSA and MSSA isolates in a Spanish hospital between 2002 and 2006
Abstract number: P1731
García-Cañas A., García-Hierro P., Sánchez-Rubio J., Rodríguez-Salvanés F., Alós J.I.
In recent years increased MICs of vancomycin has been described in meticillin-resistant Staphylococcus aureus (MRSA). The objetive of this study was to evaluate MIC trends of vancomycin and teicoplanin in clinical MRSA and meticillin-susceptible S. aureus (MSSA) isolates over a 5 year period (20022006).
MICs of vancomycin and teicoplanin were studied by broth microdilution in 567 MRSA and 2,575 MSSA clinical strains (one per patient) isolated between 2002 to 2006. BHI broth with 4 mg/L of vancomycin was used to screen vancomycin resistance. MICs of each antibiotic obtained in the different years was compared by the linear trend chi-square test.
All isolates were susceptible to vancomycin and teicoplanin. No statistically significant diference was observed in vancomycin for MRSA (X2 = 0.01; p = 0.91), and for MSSA (X2 = 0.08; p = 0.78). No statistically significant diference was observed in teicoplanin for MRSA (X2 = 3.06; p = 0.08), but a statistically significant trend to more susceptibility was observed in teicoplanin for MSSA (X2 = 5.19; p = 0.02).
Consumption of parenteral vancomycin in our Hospital in DDD/100 stays were: 2002 (1.91), 2003 (1.63), 2004 (1.74), 2005 (2.06), and 2006 (1.64). Oral vancomycin consumption for selective digestive decontamination in DDD/100 stays of ICU patients were: 2002 (63.5), 2003 (54.2), 2004 (49.5), 2005 (44.4), and 2006 (58.2).
In a scenary of few variations of vancomycin consumption, we did not notice important changes in vancomycin MICs in MRSA and MSSA clinical isolates over the period studied.
|Session name:||18th European Congress of Clinical Microbiology and Infectious Diseases|
|Back to top|